Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease
Abstract Background Vedolizumab is safe and effective in adult patients with Crohn’s disease (CD) and ulcerative colitis (UC); however, data in children with inflammatory bowel disease (IBD) are scarce. Therefore, we evaluated vedolizumab use in a cohort of Austrian paediatric patients with IBD. Met...
Main Authors: | Anna-Maria Schneider, Daniel Weghuber, Benjamin Hetzer, Andreas Entenmann, Thomas Müller, Georg Zimmermann, Sebastian Schütz, Wolf-Dietrich Huber, Judith Pichler |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-09-01
|
Series: | BMC Gastroenterology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12876-018-0868-x |
Similar Items
-
VEDOLIZUMAB IN THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES: A BRAZILIAN OBSERVATIONAL MULTICENTRIC STUDY
by: Ramir Luan PERIN, et al. -
Vedolizumab in Inflammatory Bowel Disease: West versus East
by: Prasanta Debnath, et al.
Published: (2021-01-01) -
A product review of vedolizumab in inflammatory bowel disease
by: Robert Battat, et al.
Published: (2019-10-01) -
Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases
by: Timo Rath, et al.
Published: (2018-07-01) -
Effect of Vedolizumab on Anemia of Chronic Disease in Patients with Inflammatory Bowel Diseases
by: Patrizio Scarozza, et al.
Published: (2020-07-01)